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 Genotyping of cell-free DNA (cfDNA) extracted from plasma allows minimally invasive real-time testing for 
tumor somatic genomic alterations. This approach is now increasingly recognized as clinically valid and in 
2016 the Cobas test (Roche Molecular Systems, Inc.), detecting genomic aberrations  in the epidermal 
growth factor receptor (EGFR) gene to identify patients with metastatic non-small cell lung cancer for 
treatment with erlotinib, became the first liquid biopsy assay to receive U. S. Food and Drug Administration 
approval for treatment selection 
(http://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm504540.htm). Currently, a key 
treatment decision point in metastatic prostate cancer is the selection of patients progressing after primary 
castration therapy, when the standard of care is potent AR targeting with abiraterone or enzalutamide, who 
would derive greater benefit from alternative or potentially combination treatments. Clinico-pathological 
variables sometimes used to assist this decision are primarily prognostic and have not been shown to have 
predictive utility. 
 
In this issue of Cancer Discovery, Annala and colleagues highlight this unmet need in their presentation of 
the first clinical trial to prospectively randomize patients between abiraterone or enzalutamide1. In keeping 
with previous studies, 14% (29/202) of patients had primary resistance (based on no prostate specific 
antigen [PSA] decline at 12 weeks) and 57% (116/202) had progressed within 12 months. There was no 
significant difference between either treatment in unselected patients. Given the multiple limitations with 
studying archival tumor tissue and the challenges in obtaining fresh tumor biopsies in this population, the 
authors collected plasma for exploratory biomarker analyses. They subjected plasma DNA to targeted 
capture sequencing of 72 metastatic castration-resistant prostate cancer (mCRPC) genes and for 65 cases 
with matched cfDNA and germline pairs, whole exome sequencing. Given the relatively low tumor load in 
this population, the main challenge for biomarker discovery is low circulating tumor DNA (ctDNA) fraction. A 
low ctDNA fraction limits the detection of less abundant sub-clonal aberrations and accurate estimation of 
copy number changes, especially mono-allelic deletions. Using the detected presence of somatic mutations 
for estimation, the authors identified approximately half the population as having a ctDNA fraction greater 
than 2% (115/201 patients). Patients with a ctDNA fraction 2-30% had a worse outcome than <2% and 
>30% had the worst. The authors limited genomic analysis to patients with detected ctDNA <2%. This has 
important implications in interpreting the results as the selection of a worse prognosis cohort could result in 
differences compared to studies that have tested archival tissue or germline DNA and been more inclusive. 
The authors identify changes commonly described in tumor biopsies of mCRPC but of note that tumor 
 biopsy studies are also biased by the feasibility of tumor to biopsy and often enriched for more heavily 
treated patients or disease presenting with the more aggressive features of soft tissue or visceral 
metastases.  
Using cox regression univariate analysis for a series of specific pre-determined gene aberrations or 
pathways, the authors did not identify associations with neither SPOP mutations nor WNT pathway defects. 
This is in contrast to a recent study on 75 bone and soft tissue biopsies from patients treated with 
abiraterone that found enrichment for aberrations in the Wnt/-catenin pathway in non-responders2. Annala 
et al identified significant hazard ratios for TP53 alterations, BRCA2/ATM mutations, AR gain, RB defects 
and PI3K pathway defects. They then proceeded to perform multivariate analysis including clinical 
prognostic factors, ctDNA fraction and each individual genomic aberration in turn as a covariate and report 
significant associations between shorter time to progression and deleterious alterations in TP53 and 
mutations in either of the homologous recombinant repair (HRR) genes BRCA2 or ATM. Loss of TP53 
occurring concurrently with loss of RB was recently shown in preclinical models to promote differentiation to 
a neuroendocrine phenotype that associates with resistance to AR targeting3. The TP53 aberrant 
population included here could therefore be enriched for this sub-type of AR indifferent cancers. Due to the 
limitations of detecting genomic losses at ctDNA fractions <30%, comprehensive quantitation of Rb loss in 
this cohort was not reliable. Integration with distinct methylation changes recently shown to associate with a 
neuroendocrine phenotype could further improve on genomic-based detection of this sub-type3. Men with 
localized prostate cancer harboring a germline BRCA2 variant have a shorter time to development of 
metastases but several retrospective studies have recently suggested no worse outcome with AR targeting 
therapies or taxanes in mCRPC with aberrations in DNA damage repair genes 4,5. The PRO-REPAIR 
prospective observational study has also not identified worse outcomes for mCRPC patients on first-line 
targeted AR therapy harboring BRCA or ATM germline variants6. These seemingly discordant reports 
highlight the challenges that underlie potential differences in outcome for distinct aberrations within the 
same gene or different genes within the same class, germline carriers that do not suffer a second hit, 
technologies that have differential sensitivities and analysis in a worse prognosis group selected by virtue 
of being amenable to tumor biopsy or circulating DNA tumor fraction. Moreover, given the prevalence of 
HRR defects is <20%, the numbers of affected patients in these cohorts are relatively small and this could 
also account for these variances. Importantly, detection of patients with HRR gene defects in plasma, 
potentially in combination with germline analysis, introduces the opportunity to target treatment, for 
 example with PARP inhibitors, especially in this patient population with low volume metastases where 
tissue access is challenging. The study also detected 2 patients with mismatch repair defects who could be 
selected for immune checkpoint blockade. Finally, the detection of deletions could be supported by using 
allele specific information at germline heterozygous SNPs within the region of interest as has been 
performed for other areas of truncal gene loss7.  
 
The study confirms the lack of clinical utility of AR ligand binding mutations in this setting where L702H and 
T878A are rarely detected at allelic frequencies above 2%8. The clinical relevance of detecting mutations at 
lower allelic frequencies is unclear. AR copy number gain has previously been associated with worse 
outcome independently of clinical variables on multivariate analysis8. Differences in cut-offs for defining 
amplification, such as AR gain, could lead to studies including patients with different outcomes. AR on 
chromosome X is present as one copy in normal cells but recent studies have suggested that two AR 
copies in plasma most accurately splits the population into two prognostically-defined groups8. This would 
also account for differences in reported prevalence: 15% previously and approximately double in the 
current study. The authors implement an elegant approach to correct AR copy number for ctDNA fraction. 
The interpretation of this adjustment is however limited due to not all the cells within the tumor 
compartment harboring a uniform AR copy number as has been previously shown in circulating tumor cells 
and tissue (Fig 1). This challenge could be in-part circumvented by tracking specific AR genomic structural 
rearrangements (AR-GSRs). These have been associated with being enriched in cancers harboring  AR 
amplification and/or disruptive events leading to loss of transcription of the ligand-binding domain1. 
Detection of AR splice variants particularly AR-V7 has been correlated with poor responses to abiraterone 
or enzalutamide 9. Annala et al’s exploratory analysis of AR-GSRs in plasma from a limited number of 
patients suggests they associate with primary resistance and could be used to comprehensively identify AR 
aberrant patients with genomic perturbations and a range of genomically-driven splicing variants. This 
alone may however be insufficient with recent studies also suggesting that nuclear protein expression more 
strongly associates with worse outcome than solely detection of cellular splice variants10. This could require 
composite tests that incorporate a variety of blood-based assays.  
 
Overall, interpretation of plasma DNA analysis addressing predictive questions needs to be recognized in 
the context of detection of an aberration being more likely with higher tumor fractions that in themselves are 
prognostic. Moreover, we need to increasingly utilize contemporary mathematical tools to evaluate 
 associations with outcome from cutting-edge molecular data, for example modern Bayesian approaches 
that maintain effectiveness with 1000s of variables. Finally, the discoveries in this study are but the start of 
the long road to implementation of a biomarker test for mCRPC. Putative biomarkers will need to be 
confirmed in additional cohorts’ representative of the target population and then fixed in an analytically 
validated assay prior to clinical qualification in prospective trials where the biomarker test is used for 
treatment decisions. Same as for Odysseus whose homecoming was successful but not as expected, the 
treatment decision point for abiraterone, enzalutamide or docetaxel will shift over the next few years with 
many patients increasingly receiving these treatments at start of primary androgen deprivation therapy. 
Nonetheless the strategy presented here allowing broad, real-time and accurate genomic characterization 
of a high proportion of metastatic prostate cancer patients without the need for tissue biopsies at a stage in 
the disease when multiple treatment options are available introduces a vision of future patient management 
that is likely to become routine.  
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Figure 1). The odyssey of a plasma biomarker test. A) The Biomarker Road Map, B) Overview of factors that 
can give rise to the observed copy number gains and losses in plasma across different ctDNA fractions and 
challenges in identifying what is associated with poor clinical outcome. C) The effect of estimated ctDNA 
fraction and observed copy number in interpreting the average copy number change in assessed ctDNA 
fraction. Copy number (CN), Mutant Allele Frequency (MAF). Circulating tumor DNA (ctDNA). 
